Glaucoma is an eye condition in which the optic nerve is damaged. Glaucoma is often linked to an elevated intraocular pressure (IOP) due to a blockage or malfunction of the eye drainage system. In the healthy eye, in fact, a small amount of aqueous humor (the liquid present inside the eyeball) is continuously produced, circulates and flows out of the eye to maintain a constant ocular pressure. In glaucoma, the aqueous humor does not escape properly from the eye, causing an increase in fluid pressure in the eye which, over time, will cause damage to the optic nerve fibers. The main risk factors for the development of ocular glaucoma are age, race and family history of glaucoma. Current drugs are intended to reduce high IOP to slow the progression of the disease.
Coqun is indicated as a complementary treatment to hyponizing therapy in glaucoma, thanks to its ability to counteract the oxidative damage strictly linked to the pathology.
CoQun is a buffered isotonic solution based on antioxidants such as Coenzyme Q10 and vitamin E TPGS (a form of water-soluble vitamin E, obtained from the esterification of polyethylene glycol 1000 with d-alpha tocopheryl succinate). Esterification made it possible to solubilize Coenzyme Q10. Coenzyme Q10 is an endogenous antioxidant, which performs 3 important actions:
-Bioenergetic action, which promotes the synthesis of ATP, an indispensable molecule during the wound healing process and regeneration of the corneal sub basal plexus.
-Antiapoptotic action on keratocytes and corneal fibroblasts which contributes to the repair of injured epithelia.
-Anti-inflammatory action that inhibits the expression of genes responsible for the synthesis of pro-inflammatory molecules such as TNF-α, through inhibition of NF-kB.